ACP5 and bacterial urinary tract infection: Thus, in vitro and in vivo pharmacokinetic (PK) studies were conducted to assess the stability of BAP and pro-hpAP in plasma and liver and evaluate their exposure in the urinary tract to inform on the viability of these compounds in mouse models of UTI.